{
    "clinical_study": {
        "@rank": "38532", 
        "arm_group": [
            {
                "arm_group_label": "DLBS1442, 3 x 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "DLBS1442 capsules 3x100 mg daily, taken every day along the study period"
            }, 
            {
                "arm_group_label": "DLBS1442, 3 x 200 mg", 
                "arm_group_type": "Experimental", 
                "description": "DLBS1442 capsules 3x200 mg daily, taken every day along the study period"
            }, 
            {
                "arm_group_label": "Mefenamic acid", 
                "arm_group_type": "Active Comparator", 
                "description": "Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days at minimum, during the menstrual period, i.e. day 1st to day 5th or to the last day (whichever is longer) of menstrual period."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 3-arm, prospective, randomized, double-blind, and controlled study of DLBS1442 for\n      the treatment of pain in patients suspected endometriosis. It is hypothesized that the\n      reduction of the composite-pain intensity (as measured by VAS) from baseline to the end of\n      study (week 8th) resulting from administration of DLBS1442, regardless of the dosage\n      regimen, is significantly greater than that of Control. In addition, the administration of\n      DLBS1442 at higher dose also results in significantly greater reduction than that of\n      DLBS1442 at lower dose and of Control."
        }, 
        "brief_title": "DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Patients Suspected Endometriosis", 
            "Moderate or Severe Pain on VAS", 
            "Willing to Postpone the Surgical Therapy"
        ], 
        "condition_browse": {
            "mesh_term": "Endometriosis"
        }, 
        "detailed_description": {
            "textblock": "There will be three groups of treatment by dosage regimen in this study. Eligible subjects\n      will be randomized to receive any of the following regimens: 1) DLBS1442 at a dose of 3 x\n      100 mg daily, or 2) DLBS1442 at a dose of 3 x 200 mg daily; or 3) mefenamic acid at a dose\n      of 3 x 500 mg daily. DLBS1442 will be taken every day along the study period (8 weeks),\n      while mefenamic acid will only be taken for five (5) days at minimum, during the menstrual\n      period, i.e. day 1st to day 5th or to the last day (whichever is longer) of menstrual\n      period. Study treatment will be given for 8 weeks. Clinical and laboratory examinations to\n      evaluate the investigational drug's efficacy and safety will be performed at baseline and\n      every 4-week interval throughout the study period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female of 18 - 50 years of age\n\n          -  Subjects suspected with cystic endometriosis or adenomyosis confirmed by transvaginal\n             ultrasonography (or transrectal ultrasonography for unmarried subjects)\n\n          -  Presence of moderate or severe pain as shown by VAS score or at least 4 on at least\n             one of the following pain: menstrual pain (dysmenorrhea), dyspareunia, non-menstrual\n             pelvic pain, dysuria, dyschezia\n\n          -  Occurence of at least 3 last sequential menstrual cycles of 21 - 35 days duration\n             prior to screening\n\n          -  Adequate liver and renal function\n\n          -  Willingness to postpone surgical therapy for at least 2 months\n\n          -  Able to take oral medicine\n\n        Exclusion Criteria:\n\n          -  Pregnancy or willing to be pregnant\n\n          -  Using hormonal contraception or other forms of hormonal therapy\n\n          -  Being under therapy with systemic corticosteroids on a chronic or regular basis\n             within the last 90 days\n\n          -  History or presence of suspected malignancy abnormalities\n\n          -  History of surgical treatment for endometriosis within 3 months prior to screening\n\n          -  History of hysterectomy or oophorectomy\n\n          -  Presence of clinical signs of sexually transmitted disease\n\n          -  Presence of unexplained uterine or cervical bleeding\n\n          -  Any other disease state or uncontrolled illnesses, which judged by the investigator,\n             could interfere with trial participation or trial evaluation\n\n          -  Known or suspected allergy to similar products\n\n          -  Subjects with concurrent herbal medicines or food supplements and any treatments\n             suspected to interfere with the efficacy endpoints\n\n          -  Enrolled in another interventional study within the last 30 days"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942122", 
            "org_study_id": "DLBS1442-0212"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DLBS1442, 3 x 100 mg", 
                    "DLBS1442, 3 x 200 mg"
                ], 
                "description": "Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily or DLBS1442 at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).", 
                "intervention_name": "DLBS1442", 
                "intervention_type": "Drug", 
                "other_name": "Dismeno"
            }, 
            {
                "arm_group_label": "Mefenamic acid", 
                "description": "Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days at minimum, during the menstrual period, i.e. day 1st to day 5th or to the last day (whichever is longer) of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).", 
                "intervention_name": "Mefenamic acid", 
                "intervention_type": "Drug", 
                "other_name": "Pondex Forte"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mefenamic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DLBS1442", 
            "Endometriosis", 
            "pain", 
            "VAS", 
            "EHP-30"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "contact": {
                "email": "kanadisuma@yahoo.com", 
                "last_name": "Kanadi Sumapraja, SpOG(K), MD", 
                "phone": "+6221 3928720"
            }, 
            "contact_backup": {
                "email": "wiwekobudi@yahoo.co.id", 
                "last_name": "Budi Wiweko, SpOG(K), MD", 
                "phone": "+6221 39831098"
            }, 
            "facility": {
                "address": {
                    "city": "Central Jakarta", 
                    "country": "Indonesia", 
                    "state": "Jakarta", 
                    "zip": "10430"
                }, 
                "name": "Yasmin Clinic, Division of Reproductive, Endocrinology, and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "R. Muharam, SpOG(K), MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andon Hestiantoro, SpOG(K), MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Budi Wiweko, SpOG(K), MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Herbert Situmorang, SpOG(K), MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gita Pratama, SpOG(K), MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Achmad K Harzif, SpOG, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Shanty Olivia, SpOG, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mila Maidarti, SpOG, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "3", 
        "official_title": "Role of DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis", 
        "overall_contact": {
            "last_name": "Kanadi Sumapraja, SpOG(K), MD", 
            "phone": "+6221 3928720"
        }, 
        "overall_official": {
            "affiliation": "Division of Reproductive, Endocrinology, and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital", 
            "last_name": "Kanadi Sumapraja, SpOG(K), MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction of the intensity of composite-pain (dysmenorrhea, dyspareunia, non-menstrual chronic pelvic pain, dysuria, dyschezia) as measured by Visual Analogue Scale (VAS).", 
            "measure": "Reduction of intensity (VAS)of composite-pain", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reduction of the intensity of each pain (dysmenorrhea, dyspareunia, non-menstrual chronic pelvic pain, dysuria, dyschezia) as measured by Visual Analogue Scale (VAS).", 
                "measure": "Reduction of the intensity of each pain", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Response rate is defines as percentage of subjects at the end of study experiencing a reduction of VAS score of >= 3 or >= 30% as compared to baseline, in each of the composite pain found at baseline (i.e. dysmenorrhea, dyspareunia, non-menstrual pelvic pain, dysuria, or dyschezia).", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Improvement of quality of life is measured by Endometriosis Health Profile (EHP-30) questionnaire score.", 
                "measure": "Improvement of quality of life", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Reduction in serum CA-125", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Change of IL-6", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Number of rescue medication (pain relieving drug, i.e. ibuprofen 400 mg tablet) needed during the course of the study.", 
                "measure": "Number of rescue medication needed during the course of the study", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Time to the first day on which subjects take rescue medication (pain-free period)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Percentage or proportion of subjects who complete the study (2 cycles)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Electrocardiography", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Vital signs measured include: blood pressure, heart rate, respiratory rate.", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Liver function measured includes: serum ALT (SGPT), serum AST (SGOT), and alkaline phosphatase (AP).", 
                "measure": "Liver function", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Renal function measured includes: serum creatinine and blood urea nitrogen (BUN).", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Routine hematology measured includes: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count.", 
                "measure": "Routine hematology", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Adverse event will be observed and managed along the study course.", 
                "measure": "Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "1 - 12 weeks"
            }
        ], 
        "source": "Dexa Medica Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexa Medica Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}